- Home
- CTO vs CRMD Comparison
CTO vs CRMD Comparison
Compare CTO & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTO
- CRMD
- Stock Information
- Founded
- CTO 1902
- CRMD 2006
- Country
- CTO United States
- CRMD United States
- Employees
- CTO N/A
- CRMD N/A
- Industry
- CTO Real Estate Investment Trusts
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- CTO Real Estate
- CRMD Health Care
- Exchange
- CTO Nasdaq
- CRMD Nasdaq
- Market Cap
- CTO 578.8M
- CRMD 576.4M
- IPO Year
- CTO N/A
- CRMD 2010
- Fundamental
- Price
- CTO $19.63
- CRMD $11.90
- Analyst Decision
- CTO Strong Buy
- CRMD Strong Buy
- Analyst Count
- CTO 4
- CRMD 6
- Target Price
- CTO $21.50
- CRMD $15.67
- AVG Volume (30 Days)
- CTO 418.8K
- CRMD 1.2M
- Earning Date
- CTO 02-20-2025
- CRMD 10-30-2024
- Dividend Yield
- CTO 7.74%
- CRMD N/A
- EPS Growth
- CTO N/A
- CRMD N/A
- EPS
- CTO 0.61
- CRMD N/A
- Revenue
- CTO $118,662,000.00
- CRMD $12,262,234.00
- Revenue This Year
- CTO N/A
- CRMD N/A
- Revenue Next Year
- CTO $13.12
- CRMD $300.00
- P/E Ratio
- CTO $32.41
- CRMD N/A
- Revenue Growth
- CTO 16.61
- CRMD 41184.20
- 52 Week Low
- CTO $16.16
- CRMD $2.89
- 52 Week High
- CTO $21.15
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- CTO 50.11
- CRMD 73.05
- Support Level
- CTO $18.89
- CRMD $7.91
- Resistance Level
- CTO $19.74
- CRMD $11.50
- Average True Range (ATR)
- CTO 0.36
- CRMD 0.56
- MACD
- CTO 0.01
- CRMD 0.44
- Stochastic Oscillator
- CTO 72.55
- CRMD 98.66
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a Florida-based real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.